Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.

Authors: Xiang, Y  Zhu, Z  Han, G  Ye, X  Xu, B  Peng, Z  Ma, Y  Yu, Y  Lin, H  Chen, AP  Chen, CD 
Citation: Xiang Y, etal., Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19226-31. Epub 2007 Nov 28.
Pubmed: (View Article at PubMed) PMID:18048344
DOI: Full-text: DOI:10.1073/pnas.0700735104

Histone methylation is a dynamic process that participates in a diverse array of cellular processes and has been found to associate with cancer. Recently, several histone demethylases have been identified that catalyze the removal of methylation from histone H3 lysine residues. Through bioinformatic and biochemical analysis, we identified JARID1B as a H3K4 demethylase. Overexpression of JARID1B resulted in loss of tri-, di-, and monomethyl H3K4 but did not affect other histone lysine methylations. In vitro biochemical experiments demonstrated that JARID1B directly catalyzes the demethylation. The enzymatic activity requires the JmjC domain and uses Fe(II) and alpha-ketoglutarate as cofactors. Furthermore, we found that JARID1B is up-regulated in prostate cancer tissues, compared with benign prostate samples. We also demonstrated that JARID1B associates with androgen receptor and regulates its transcriptional activity. Thus, we identified JARID1B as a demethylase capable of removing three methyl groups from histone H3 lysine 4 and up-regulated in prostate cancer.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 9587744
Created: 2014-10-16
Species: All species
Last Modified: 2014-10-16
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.